Serotypes and Antimicrobial Resistance of Isolates Causing Invasive Pneumococcal Disease in Adult Patients in Portugal After the 13-Valent Conjugate Vaccine Received an Adult Indication, 2012–2014 | Zendy

Andreia N. Horácio | Zendy; Catarina Silva-Costa | Zendy; Joana Lopes | Zendy; Mário Ramirez | Zendy; José MeloCristino | Zendy

Open Access

Serotypes and Antimicrobial Resistance of Isolates Causing Invasive Pneumococcal Disease in Adult Patients in Portugal After the 13-Valent Conjugate Vaccine Received an Adult Indication, 2012–2014

Author(s) -

Andreia N. Horácio,

Catarina Silva-Costa,

Joana Lopes,

Mário Ramirez,

José MeloCristino

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw172.652

Subject(s) - medicine , serotype , pneumococcal disease , antimicrobial , antibiotic resistance , pneumococcal conjugate vaccine , streptococcus pneumoniae , microbiology and biotechnology , virology , conjugate vaccine , antibiotics , biology

To prevent IPD there are currently three vaccines available – two polysaccharide conjugate vaccines, covering 10 and 13 serotypes (PCV10 and PCV13, respectively) and one polysaccharide vaccine, targeting 23 serotypes (PPV23). In Portugal, PCV13 has been the most widely used pneumococcal vaccine in children since its introduction, in early 2010 (>60% coverage in 2012). In 2015, PCV13 vaccine was included in the national immunization program (NIP) for children. For adults, PCV13 and PPV23 are available since 2012 and 1996, respectively, but with low usage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research